表紙
市場調査レポート

アフリカトリパノソーマ症:パイプライン製品の分析

African Trypanosomiasis - Pipeline Review, H1 2016

発行 Global Markets Direct 商品コード 265423
出版日 ページ情報 英文 46 Pages
即納可能
価格
本日の銀行送金レート: 1USD=102.95円で換算しております。
Back to Top
アフリカトリパノソーマ症:パイプライン製品の分析 African Trypanosomiasis - Pipeline Review, H1 2016
出版日: 2016年03月22日 ページ情報: 英文 46 Pages
概要

アフリカトリパノソーマ症、別名アフリカ睡眠病は、寄生虫ブルーストリパノソーマによる感染症で、ツェツェバエの刺咬によりヒトに伝播します。不安感、日中の傾眠、発熱、頭痛、不眠、気分の変動、眠気(抑制不能な場合もあり)、発汗、身体中のリンパ節腫脹、刺咬部の腫れ、発赤、痛みを持った結節化、筋力低下などの症状があり、抗原虫薬などの治療法があります。

当レポートでは、世界におけるアフリカトリパノソーマ症治療薬のパイプラインについて取り上げ、現在の開発パイプラインの状況や最新動向、薬剤プロファイル、主要企業および開発中の製品レビューなどをお届けいたします。

目次

イントロダクション

  • 分析範囲

アフリカトリパノソーマ症の概要

治療薬の開発

  • アフリカトリパノソーマ症向けパイプライン製品:概要
  • アフリカトリパノソーマ症向けパイプライン製品:比較分析

アフリカトリパノソーマ症:開発中の治療薬:企業別

アフリカトリパノソーマ症:開発中の治療薬:大学・研究機関別

アフリカトリパノソーマ症:パイプライン製品の概況

  • 治験段階の製品
  • 初期段階の製品

アフリカトリパノソーマ症:開発中の製品:企業別

アフリカトリパノソーマ症:開発中の製品:大学・研究機関別

アフリカトリパノソーマ症:治療薬開発に従事している企業

  • Anacor Pharmaceuticals, Inc.
  • Sanofi
  • Scynexis, Inc

アフリカトリパノソーマ症:治療薬の評価

  • 単剤治療薬
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤プロファイル

  • フェキシニダゾール
  • AN-4169
  • AN-5568
  • DDD-100097
  • fexinidazole
  • LH-7
  • 睡眠病向けペプチド
  • アフリカトリパノソーマ症向け小分子
  • マラリア・アフリカトリパノソーマ症向け小分子
  • 原虫感染向け小分子
  • 睡眠病向け小分子
  • アフリカトリパノソーマ症向けロイシルtRNAシンテターゼ (LeuRS) 阻害小分子
    • 製品概要
    • 作用機序
    • R&Dの進捗

最新のパイプライン動向

休止中のプロジェクト

開発中止の製品

製品開発マイルストーン

  • 注目のニュース・プレスリリース

付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC7754IDB

Summary

Global Markets Direct's, 'African Trypanosomiasis - Pipeline Review, H1 2016', provides an overview of the African Trypanosomiasis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for African Trypanosomiasis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for African Trypanosomiasis and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of African Trypanosomiasis
  • The report reviews pipeline therapeutics for African Trypanosomiasis by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved African Trypanosomiasis therapeutics and enlists all their major and minor projects
  • The report assesses African Trypanosomiasis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for African Trypanosomiasis

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for African Trypanosomiasis
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding African Trypanosomiasis pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • African Trypanosomiasis Overview
  • Therapeutics Development
    • Pipeline Products for African Trypanosomiasis - Overview
    • Pipeline Products for African Trypanosomiasis - Comparative Analysis
  • African Trypanosomiasis - Therapeutics under Development by Companies
  • African Trypanosomiasis - Therapeutics under Investigation by Universities/Institutes
  • African Trypanosomiasis - Pipeline Products Glance
    • Clinical Stage Products
    • Early Stage Products
  • African Trypanosomiasis - Products under Development by Companies
  • African Trypanosomiasis - Products under Investigation by Universities/Institutes
  • African Trypanosomiasis - Companies Involved in Therapeutics Development
    • Anacor Pharmaceuticals, Inc.
    • Sanofi
    • Scynexis, Inc.
  • African Trypanosomiasis - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • AN-4169 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • AN-5568 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • DDD-100097 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • fexinidazole - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Peptides for Sleeping Sickness - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules for African Trypanosomiasis - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules for Malaria and African Trypanosomiasis - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules for Protozoal Infections - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules for Sleeping Sickness - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Inhibit Leucyl-tRNA Synthetase (LeuRS) for Human African Trypanosomiasis - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Inhibit N-Myristoyltransferase for African Trypanosomiasis - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • African Trypanosomiasis - Recent Pipeline Updates
  • African Trypanosomiasis - Dormant Projects
  • African Trypanosomiasis - Discontinued Products
  • African Trypanosomiasis - Product Development Milestones
    • Featured News & Press Releases
      • Sep 08, 2015: Clinical trial for first oral drug candidate specifically developed for sleeping sickness
      • Mar 12, 2012: Anacor Announces Commencement Of Phase I Clinical Trials Of Boron-Based Compound For Sleeping Sickness
      • Jun 28, 2011: Anacor Pharmaceuticals Partnership Advances New Drug Candidate To Combat Sleeping Sickness
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for African Trypanosomiasis, H1 2016
  • Number of Products under Development for African Trypanosomiasis - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Development, H1 2016
  • Products under Development by Companies, H1 2016
  • Products under Investigation by Universities/Institutes, H1 2016
  • African Trypanosomiasis - Pipeline by Anacor Pharmaceuticals, Inc., H1 2016
  • African Trypanosomiasis - Pipeline by Sanofi, H1 2016
  • African Trypanosomiasis - Pipeline by Scynexis, Inc., H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Number of Products by Stage and Target, H1 2016
  • Number of Products by Stage and Mechanism of Action, H1 2016
  • Number of Products by Stage and Route of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
  • African Trypanosomiasis Therapeutics - Recent Pipeline Updates, H1 2016
  • African Trypanosomiasis - Dormant Projects, H1 2016
  • African Trypanosomiasis - Discontinued Products, H1 2016

List of Figures

  • Number of Products under Development for African Trypanosomiasis, H1 2016
  • Number of Products under Development for African Trypanosomiasis - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Number of Products by Targets, H1 2016
  • Number of Products by Stage and Targets, H1 2016
  • Number of Products by Mechanism of Actions, H1 2016
  • Number of Products by Stage and Mechanism of Actions, H1 2016
  • Number of Products by Stage and Routes of Administration, H1 2016
  • Number of Products by Molecule Types, H1 2016
  • Number of Products by Stage and Molecule Types, H1 2016
Back to Top